Usual Adult Dose for Hypotrichosis of the Eyelashes

Apply 1 drop to the upper eyelid margin of each eye once a day at night

Application:

• Apply topically to clean, makeup-free skin using the supplied sterile applicators with 1 applicator for each eye.
• Place 1 drop of this drug on an applicator; apply evenly along the skin of the upper eyelid at base of lashes.
• Following administration, upper lid margin should feel lightly moist; if there is runoff, blot with a tissue or absorbent cloth.
• Repeat for the opposite eyelid margin using a new sterile applicator.

• Additional drops or applications will not increase eyelash growth.
• Eyelash growth is expected to return to pretreatment levels upon drug discontinuation.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

• Hypersensitivity to the active component or any of the ingredients

Dialysis

Data not available

Other Comments

Administration advice:

• Apply once a day at night
• Prior to application, remove makeup and contact lenses, clean and dry face
• Place 1 drop on applicator and apply evenly along the skin of the upper eyelid at base of lashes
• Blot any runoff solution with a tissue or absorbent cloth
• Do not apply to lower eyelids
• Repeat dosing application to the opposite eyelid using a new applicator (1 drop per eye, each on a new applicator)
• Use only the supplied single-use disposable applicators
• Avoid allowing bottle tip or sterile applicator to contact fingers or any other unintended surface to avoid contamination
• Discard disposable applicator after use

• Onset of effect is gradual (significant at approximately 2 months). The effects of this drug are not permanent.
• Any solution that gets into the eye will not cause harm and should not be rinsed.

• OCULAR: Patients using concomitant prostaglandin analogs should be monitored for changes to intraocular pressure.

• Patients should be told that additional drops or applications will not increase eyelash growth.
• Patients should be advised that this drug may cause eyelid skin darkening that may be reversible after discontinuation.
• Patients should be warned that this drug may increase brown pigmentation of the iris, which is likely to be permanent.
• Patients should be instructed to avoid application to skin surrounding the treatment area as unexpected hair growth may occur in areas repeatedly exposed to this drug.
• Patients should be told to contact their healthcare provider if a new ocular condition occurs (e.g., trauma, infection, hypersensitivity reaction, surgery), or for any sudden decrease in vision.